Agilent (A) announced an agreement with Incyte (INCY) that will bring together Agilent’s expertise in the development of companion diagnostics, or CDx, to support the development and commercialization of Incyte’s hematology and oncology portfolio. The agreement between Agilent and Incyte allows the companies to collaborate on CDx development programs. This will enable Agilent to continue to expand its companion diagnostics portfolio with novel biomarkers and Incyte to leverage Agilent’s expertise in IVD assay development, global regulatory approvals, and commercialization to support clinical trials as well as the potential registration and commercialization of CDx in the United States and Europe.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on A:
- Agilent price target raised to $120 from $100 at Barclays
- Agilent moves Cell Analysis Division into DGG to strengthen growth opportunities
- Agilent initiated with bullish view at Wolfe Research, here’s why
- Agilent initiated with bullish view at Wolfe Research
- Agilent just downgraded at BofA, here’s why
